Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;27(3):1601-1604.
doi: 10.1111/dom.16152. Epub 2025 Jan 2.

Glucagon-like peptide-1 analogues reduce alcohol intake

Maurice O'Farrell  1 , Faisal I Almohaileb  2 , Carel W le Roux  3
Affiliations

Glucagon-like peptide-1 analogues reduce alcohol intake

Maurice O'Farrell et al. Diabetes Obes Metab. 2025 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

F.A. reports no competing interests. M.O'.F provides obesity clinical care in the Medication Weight Loss Clinic and is the owner of this clinic. M.O'.F has served on advisory boards for Novo Nordisk and Johnson & Johnson, both positions unremunerated. C.l.R reports grants from the EU Innovative Medicine Initiative, Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards and speakers panels of Novo Nordisk, Roche, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Gila, Irish Life Health, Boehringer Ingelheim, Currax, Zealand Pharma, Keyron, AstraZeneca, Arrowhead Pharma, Amgen, and Rhythm Pharma. C.l.R is the Chair of the Irish Society for Nutrition and Metabolism. C.l.R provides obesity clinical care in the My Best Weight clinic and Beyond BMI clinic and is a shareholder.

Figures

FIGURE 1
FIGURE 1
Alcohol intake before intervention.
FIGURE 2
FIGURE 2
Alcohol intake reduction after intervention.
See this image and copyright information in PMC

References

    1. World Health Organization . Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders. World Health Organization; 2024. Licence: CC BY‐NC‐SA 3.0 IGO.
    1. Farokhnia M, Browning BD, Crozier ME, Sun H, Akhlaghi F, Leggio L. The GLP‐1 system is modulated by acute and chronic alcohol exposure: findings from human laboratory experiments and a post‐mortem brain study. Addict Biol. 2022;27(5):e13211. doi: 10.1111/adb.13211 - DOI - PMC - PubMed
    1. Weiss F. Neurobiology of craving, conditioned reward, and relapse. Curr Opin Pharmacol. 2005;5(1):9‐19. doi: 10.1016/j.coph.2004.11.001 - DOI - PubMed
    1. Vallöf D, Kalafateli AL, Solinas M, et al. The GLP‐1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016;21(2):422‐437. doi: 10.1111/adb.12295 - DOI - PMC - PubMed
    1. Wang W, Heilig M, Volkow ND, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in a real‐world population. Nat Commun. 2024;15(1):4. doi: 10.1038/s41467-024-48780-6 - DOI - PMC - PubMed

LinkOut - more resources